NCT02242097

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2015-01-12Est. Completion: 2021-12-07

Enrollment target: 37 participants

Locations

Northwestern University, Chicago, Illinois, United States
Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cleveland Clinic, Cleveland, Ohio, United States
University of Utah, Salt Lake City, Utah, United States

Other microbiome trials you might be interested in

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaPhase 1Recruiting

Ann Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III Mantle Cell LymphomaAnn Arbor Stage IV Mantle Cell Lymphoma

This phase I trial tests the safety, side effects and best dose of glofitamab given with alternating cycles of rituximab…

Multiple LocationsEst. completion Sep 1, 2027

View Trial →

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasPhase 1Completed

Adult Grade III Lymphomatoid GranulomatosisB-cell Chronic Lymphocytic LeukemiaContiguous Stage II Adult Diffuse Large Cell LymphomaContiguous Stage II Adult Diffuse Mixed Cell Lymphoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.